A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

RCT (n=425) reports mean change in Positive and Negative Symptom Scale (PANSS) score at week 4 of −17.2 points and −9.7 points respectively for SEP-363856 and placebo (least-squares mean difference, −7.5 points; 95% CI −11.9 to −3.0; P=0.001).

SPS commentary:

SEP-363856 represents a new class of psychotropic agent that does not act on dopamine D2 receptors, but has agonist activity at trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A) receptors.


New England Journal of Medicine